DEGRADATIVE ENZYMES IN OSTEOARTHRITIS

R. Lane Smith

Stanford University School of Medicine, Department of Functional Restoration, Stanford, California and Veterans Affairs Palo Alto Health Care System, Palo Alto, California

TABLE OF CONTENTS

1. ABSTRACT

A central feature of the osteoarthritic disease process involves erosive destruction of the articular cartilage extracellular matrix (ECM) on the surfaces of diarthrotic joints. The resultant loss of joint function makes studies on mechanisms underlying ECM degradation critical for treatment of the disease and prevention of disability. Candidate pathways to account for the loss of cartilage involve expression of a combination of proteases that degrade the major cartilage matrix macromolecules, aggrecan and type II collagen. The specific types of enzymatic activities associated with the progressive removal of ECM and severity of joint disease include the matrix metalloproteinases, collagenase, gelatinase and aggrecanase(s). The degradative enzymes originate in synovial cells, cartilage cells, the chondrocytes, distributed within the ECM and leukocytes that actively invade the joint space. Specific enzymes arising from each of these tissues exhibit selective ECM degrading properties; the different categories of these tissue-derived enzymes will be discussed in this chapter. A perspective on the efficacy of existing agents and the potential for development of novel therapeutic agents is also included. While the degradative enzymes serve as a focal point for therapeutic intervention, a fundamental understanding of the mechanisms underlying degradative enzyme expression in osteoarthritis remains an important goal for prevention of disease.

2. INTRODUCTION

Osteoarthritis is a disease process with multiple etiologies that afflicts a majority of the population in the later decades of life. Some of the factors contributing to disease susceptibility include genetics, body mass, previous history of trauma to a major limb, occupational influences, and immobilization. The disease in all cases culminates in the stepwise degeneration of diarthrotic joint integrity and function. A principal cause of joint morbidity results from degradation of the articular cartilage extracellular matrix (ECM). Since the specialized articular cartilage ECM ensures distribution of mechanical loads generated by weight bearing, loss of function quickly follows ECM breakdown. The loss of function manifests primarily through painful and highly restricted joint movement. The impact of osteoarthritis on personal productivity and quality of life in an aging society is increasingly being recognized as an important element of health care costs. The end stage of osteoarthritis usually requires total joint replacement. The current total health care cost attributable to this procedure is estimated to be hundreds of thousands annually.

This review delineates the role of various candidate enzymes implicated as causative agents in the loss of joint function. The discussion will include a short perspective on inhibition of degradative enzyme activity as a target for therapeutic intervention. Disease processes impacted by enzymatic degradation of extracellular matrix are vast and the subject area represents a dynamic and expansive topic of current research in biology and medicine. The molecular mechanisms involved in ECM degradation encompass specialized investigations within such diverse fields as tissue differentiation, growth factor and cytokine biology, immunological cell selection models and tumor cell metastatic disease. To limit the central focus to joint disease, the subject matter covered will establish a catalog of enzymatic activities that are recognized as strong candidates in the destruction of cartilage ECM in osteoarthritis.

The information will be presented within a structural framework that is organized around the specific tissues thought to elaborate the degradative enzymes associated with the disease process. In this regard, three major tissues must be considered the synovium, the

articular cartilage and the immune lymphoid organs. The synovium is a thin tissue that lines the joint space and is the structure that defines the boundaries of the synovial cavity. However, when inflamed, the synovium contributes to joint degradation. The second tissue is articular cartilage. At first glance, the cartilage appears to be metabolically inactive and to serve solely as an inert weight-bearing tissue lining the bony surface. However, perturbation of the chondrocytes within the cartilage ECM results in the release and activation of enzymes capable of ECM degradation. The immune system is the third candidate as a source of the degradative enzymes that when stimulated, attack the cartilage ECM macromolecules.

Therapeutic agents recognized as efficacious in blocking the degradative processes that involve cartilage degrading enzymes will be described to provide some perspective on treatment. Although no definitive answers are available with respect to prevention of osteoarthritis, continued discovery of the genetic, physical and metabolic influences on joint tissue metabolism predicts a promise of significant advances in our understanding of the role of degradative enzymes in osteoarthritis.

3. ARTICULAR CARTILAGE

The functional capability of articular cartilage rests with its three primary components, water, proteoglycan and type II collagen (1-5). The water content of cartilage depends largely on the proteoglycan content. The presence of water in association with the hydrophilic and negatively charged glycosaminoglycans contributes to the compressive resilience of the tissue. Articular cartilage proteoglycans include large and small proteoglycans with varying amounts of glycosaminoglycans and oligosaccharides covalently attached to a core protein. The proteoglycans and their constituent glycosaminoglycans originate as products of the chondrocyte. The proteoglycans are transported from the cells to the extracellular environment through multiple processing steps. The chondrocytes are non-randomly distributed throughout the cartilage matrix and exhibit variation in metabolism that coincides with location (6,7). Alteration of the chondrocyte morphology also modifies collagen synthesis (8) and may contribute to release of latent degradative enzymes such as procollagenase (9).

Type II collagen is assembled as cross-linked fibrils and provides cartilage with tensile strength (10,11). Collagen is protected from denaturation by the macromolecular complexes of aggrecans (large aggregating proteoglycans) (12-17). Aggrecans consist of a core protein having a molecular weight of 200-350 kilodaltons (18-20) to which the individual glycosaminoglycan (GAG) chains, chondroitin and keratan sulfate, are attached by covalent linkages to either a serine or threonine residue (21-23). The large proteoglycans contain approximately 100 chains of chondroitin sulfate, 40-50 keratan sulfate chains, 60-70 O-linked and 6-8 N-glycosidically linked oligosaccharide chains (24). Core proteins exhibit extensive homology (> 80%) for chicken, rat and human proteoglycan (25). A number of other minor but potentially

structurally important molecules such as fibromodulin, types IX and XI collagen, decorin and cartilage oligomeric protein are interspersed within the major macromolecules, the aggrecans and type II collagen.

4. HISTORICAL VIEW

The early recognition of the extensive nature of the articular cartilage erosion from the bony surface makes the quest for the responsible agent a high priority. After years of consideration of lysosomal-like degradative enzymes, careful evaluation of lesions within human cartilage suggested a role for collagenase activity (26). In fact, studies of swelling pressure of osteoarthritic cartilage in vitro found that water content was increased. It was concluded that the increase in water content was due to a failure of the collagen network to resist expansion (27). A number of studies revealed that the joint space may remain in the neutral pH range and that proteases active at neutral pH may be significant to the degradative process (28,29). This consideration prompted a number of studies of ECM degradation to be carried out with isolated tissues.

Early studies screening degradative enzymes in homogenized cartilage collected from joints of animal models of osteoarthritis provide clues that neutral protease activity correlated with cartilage degradation. In many of the early studies, the index of degradation was the extent of the cartilage surface area showing fibrillation. Fibrillation was defined as a loss of integrity of the outer, smooth surface of the articular cartilage. The visualization of the extent of fibrillation often was achieved with particulate dye staining of the surface. Analysis of forty-nine specimens of osteoarthritic cartilage revealed increased collagenolytic activity and the highest levels of activity coincided with osteoarthritic lesions on the surface (30). Continued study of human osteoarthritic cartilage showed that proteolytic activity increased in proportion to the severity of disease and the significance of proteases as contributors to cartilage breakdown was increased by evidence that inhibiting the activity with chelators slowed the arthritic process (31). The role of the proteases active at neutral pH was extended to degradation of the proteoglycan. The effects of these enzymes on the proteoglycan became implicated in the loss of the ability of the large aggregating proteoglycans (aggrecans) to form stable non-covalently linked macromolecular complexes with hyaluronic acid. This supposition was strengthened by the demonstration that cleavage of the core protein released the hyaluronic acid binding domain from the remaining aggrecan structure (32). One important feature of the osteoarthritic cartilage was the discovery in a canine model that the degradation of the matrix was accompanied by changes in the character of the proteoglycans so that the chondroitin-sulfate chains were of a larger hydrodynamic size (33). This discovery presaged the recognition that some abortive reparative effort occurs within the ECM that may be associated with the onset of cell cloning.

5. SYNOVIAL ENZYMES

The distinction between what is a synovial-derived degradative enzyme versus a degradative enzyme

from other sources remains difficult to discern. One characteristic of osteoarthritis is that there is often evidence of synovitis at the margins of the joint but the role of synovial tissue in cartilage degradation remain unclear. In general, the floridity of the synovitis in osteoarthritis does not compare with that observed in an inflammatory disease such as rheumatoid arthritis. However, the difference in the two disease conditions permits some comparisons to be made.

Analysis of synovial fluid from an animal model of osteoarthritis showed no significant difference in the concentration of latent metalloproteinase between normal and experimental knees (34). In the same animal model, interleukin-6 levels were significantly elevated. In a model of slowly progressive osteoarthritis induced by a tibial valgus osteotomy, the synovial fluid of the operative knee exhibited increased levels of matrix metalloproteinase-3 (stromelysin) (35). At later stages of disease (18 months after surgery), the molar ratio of MMP-3 to tissue inhibitor of metalloproteinases-1 (TIMP-1) was higher in the operative knee. A comparison of the differential expression of cathepsins B and L in the synovial membrane of patients with rheumatoid arthritis and osteoarthritis revealed that matrix metalloproteinase mRNA expression was greater than cathepsin expression (36). The levels of cathepsin and metalloproteinase proteins were elevated in the rheumatoid synovial lining suggesting that post-transcriptional up-regulation of the enzymes occurred. Recent work suggests that the cathepsins may act to accelerate the degradation processes by adding to metalloproteinase activity (37). Comparison of MMP-3 levels synovial fluid of hips with osteonecrosis of the femoral head and hips with osteoarthrosis showed measurable levels of MMP-3 in both sources with levels being higher in the osteonecrosis samples (38). TIMP-1 levels were the same in both groups. Matrix metalloproteinase-13 was also measurable in the synovial stroma in samples collected from rheumatoid and osteoarthritic knees (39). The level of MMP-13 was higher in the rheumatoid synovium when compared to the osteoarthritic tissue.

An overwhelming amount of evidence from studies of synovial tissue supports the view that in chronic inflammatory conditions such as rheumatoid arthritis, synovial-derived degradative enzymes contribute to joint destruction. The same evidence suggests that synovial tissue in osteoarthritis exhibits some level of inflammatory enzymes such as MMP-3 but the synovium is not a major source of degradative activity. Such a conclusion leaves open the question of where the degradative enzymes arise in osteoarthritis. However, RT-PCR analysis of mRNA from cells from osteoarthritic synovial fluid showed the presence of matrix metalloproteinase-9 (MMP-9) signal (40).

6. CHONDROCYTE ENZYMES

Studies of normal and osteoarthritic cartilage under a variety of conditions ranging from characterization of human cartilage degradative enzymes from autopsy samples to *in situ* hybridization studies of cartilage from animal models of osteoarthritis implicate the chondrocyte in the destructive process. In normal articular cartilage, chondrocytes are metabolically active cells that are essentially non-dividing and which are primarily involved in the gradual turnover of the aggrecan components of the ECM. However, many studies have established that the chondrocyte is a cell in a state of "calm before a storm". The storm being the process activated by acute phase reactants of the inflammatory process. The proinflammatory mediators, interleukin-1 alpha and beta, tumor necrosis factor alpha and other components such as transforming growth factor beta, phospholipase A2 and oxygen intermediates are capable of triggering the activation of latent neutral metalloproteinases (41-47). Once activated, the matrix metalloproteinases represent a group of enzymes that effectively degrade the cartilage ECM in a sudden and potentially irreversible manner (48-51).

A consideration of the degradative enzymes expressed by the articular chondrocyte fails to reveal a particular enzyme that stands out as singularly critical to the disease process. Some forms of the degradative enzymes appear to be selectively changed with respect to disease condition, time in the history of disease or at a particular location on the joint surface. A pragmatic approach would suggest that multiple enzymes likely play overlapping roles particularly as different ECM components serve as substrate (52). The latent metalloproteinases also represent substrate molecules as conversion of latent forms of these enzymes contributes to a progression in the degradative cascade.

In some respects, the degradative enzyme cascade active in cartilage degradation resembles other enzymatic cascades such as that represented by the complement system. The complexity of the activation process may require a redundant regulatory activation, involving post-transcriptional and post-translational mechanism, to ensure tissue and matrix stability during periods of excessive load, prolonged infection or massive trauma.

The enzymatic activities directed at the major matrix components, collagen and aggrecan, remain the focus of investigation of cartilage ECM degradation. The early studies on arthritic cartilage initially centered on the cathepsins but this emphasis was replaced following demonstration of collagenase in the matrix (53-57). Thereafter, a number of studies confirmed the expression of a variety of matrix metalloproteinases in cartilage. The forms that have been reported to be present in varying levels depending on the state of the cartilage, include MMP-9, MMP-1, MMP-2, MMP-3, MMP-7, MMP-8, MMP-13 and membrane type 1 MMP (MT1-MMP) (58-65). RT-PCR studies of 54 osteoarthritic samples from twenty-four patients revealed that differential expression of MMP-9 mRNA coincides with severity of cartilage degradation (66). The severity of cartilage breakdown was determined by the extent of fibrillation of the surface and the mRNA expression was confirmed by *in situ*

hybridization. Importantly, this study revealed that MMP-9 expression was unregulated in osteoarthritic cartilage that exhibited a normal surface appearance. One hypothesis linking the expression of MMP-9 to inappropriate levels of mechanical loading involves the unregulated expression of the enzyme.

The role of increased collagenase activity on the cleavage of type II collagen was first suggested by the early studies confirming that active enzyme was extractable from osteoarthritic cartilage but not from normal articular cartilage (67). The role of the collagenases in the direct breakdown of type II collagen has been strengthened considerably. Immunohistological studies confirm an increased presence of neoepitopes in osteoarthritic cartilage that correspond to degraded fragments of a purified type II collagen substrate. The neoepitopes correspond to fragments produced by MMP-1 (collagenase-1), MMP-8 (collagenase-2) and MMP-13 (collagenase-3) (68). MMP-7 expression was localized to chondrocytes in the superficial and the transitional zones of osteoarthritic cartilage (69). The expression of MMP-7 showed a linear correlation with an increase in disease severity using the Mankin histological scoring system. Recent studies showed that expression of at least one member of a new family of proteins that exhibit a disintegrin-like and a metalloproteinase-like domain might also be involved in the pathobiology of osteoarthritis (70).

A central feature of the onset of cartilage degradation concerns the loss of the aggrecans from the extracellular matrix. As discussed above, the reduction of aggrecan content significantly alters the material properties of cartilage that provide much of its loading bearing function. In particular, loss of aggrecan changes both endogenous water content and the frictional resistance of water to leave the ECM. Changes in these parameters decrease compressive resilience and may contribute to disruption of the collagenous organization. Analytical studies of cartilage degradation products showed that the core protein of the aggrecans underwent cleavages that were consistent with matrix metalloproteinase specificity but also showed a unique peptide product suggestive of a different enzyme. This activity was attributed to a putative aggrecanase and more recent data implicated this enzyme in the osteoarthritic process (71). However, the fact that both the VDIPEN- and the NITEGE-neoepitopes produced from aggrecan are detected in joint cartilage indicates that multiple enzyme activities contribute to disease (72).

7. INFLAMMATORY CELL ENZYMES

The inflammatory cell enzymes include the metalloproteinases that may originate from the monocytes, macrophages and neutrophils that invade the synovial lining during inflammation. A study of MMP-9 expression in rheumatoid and inflammatory arthritis synovium showed that the leukocytes, neutrophils and macrophages, and the endothelial cells infiltrating the tissue expressed elevated levels when compared to synovial tissue from osteoarthritic joints (73). However, cells of synovial fluid samples aspirated from osteoarthritic joints exhibited significant MMP-9 expression.

The osteoarthritic joint may also exhibit an associated release of proinflammatory mediators such as interleukin-1 that may contribute to joint destruction by inducing the release of degradative enzymes (74). The activity of interleukin-1 as an inducer of cartilage matrix degradation is now understood to include induction of matrix metalloproteinase synthesis by chondrocyte and inhibition of the synthesis of the cartilage matrix components, type II collagen and aggrecan (75-77). Evidence exists that the effects of interleukin-1 on cartilage metabolism is less severe in immature cartilage when compared to cartilage obtained from animals having reached sexual maturity (78). The major age effect appeared to be the recovery of aggrecan synthesis following treatment with interleukin-1 *in vitro*. These data form the basis for considering that osteoarthritis exhibits a greater association with age because of the intrinsic susceptibility cartilage to respond to the proinflammatory cytokines. Other effects of interleukin-1 on joint tissue include an increase in chondrocyte expression of matrix metalloproteinase-9, which is elevated in the presence of protein kinase C activators (79). Interleukin-1 also increased the expression of phospholipase A2 in rabbit chondrocytes so that substrate availability for prostaglandin synthesis was increased in the joint (80).

8. HOMEOSTATIC MECHANISMS

The observation that cartilage remains intact and fully functional in some individuals over six to seven decades provides a strong argument for the existence of tightly coupled homeostatic mechanisms to ensure ECM stability. One major hypothesis addressing the longevity of ECM integrity states that a balance between levels of tissue inhibitors of matrix metalloproteinases (TIMP-1, TIMP-2, and TIMP-3) and matrix metalloproteinases (MMPs) prevents ECM degeneration (81,82). TIMP-2 was constitutively expressed by human chondrocytes and the level of expression was unchanged by serum, interleukin-1, interleukin-6 or transforming growth factor-beta. TIMP-1 expression by chondrocytes did respond to these agents (83). The expression of TIMP-3 in primary human and bovine articular chondrocytes was also increased by serum factors, including transforming growth factor-beta (84). These data suggest that differential regulation of the TIMP protein occurs in articular cartilage. A loss in regulatory factors may be responsible for an imbalance in the ratio of inhibitor to protease in osteoarthritic cartilage. A number of studies have confirmed that the relationship between these important proteins is perturbed with metalloproteinase activity being greater than TIMP levels (85-87).

Another regulatory process may involve the selective activation of the matrix metalloproteinases. A proenyzme activator of MMP-3 occurs in articular cartilage and results in the step-wise processing of the MMP-3 propeptide to generate multiple active forms of protease. The catalytic properties of the proenyzme activator share a resemblance to other metalloendopeptidases that exhibit specificity for single arginine or dibasic propeptide cleavage sites (88). Studies on membrane-type 1 MMP in

OA cartilage samples show that membranes of osteoarthritic chondrocytes can activate proMMP-2 which once activated exhibited a wide range of substrate specificity against components of the cartilage ECM (89,90)

9. PERSPECTIVE ON THERAPEUTIC AGENTS

The emphasis placed in this review on the role of metalloproteinases in cartilage matrix destruction emphasizes the need for therapeutic modalities capable of blocking their action. The involvement of the individual proteinases in the degradation of specific proteins makes the task a difficult one. The recognized role of inflammation in cartilage degradation has prompted a number of studies that evaluated agents such as the non-steroidal antiinflammatory drugs. In some instances, the NSAIDs exhibited efficacious effects on cartilage degeneration and intervention in the protease cascade (91,92). The drugs also showed some selective reactions with respect to chondrocyte metabolism (93). However, as a group, the matrix metalloproteinases remain of central interest as an appropriate target for preventing joint destruction in osteoarthritis.

Numerous studies show that members of the tetracycline family of antibiotics are effective in inhibiting collagenase and gelatinase activity (94-96). Oral administration of the one of these agents, doxycycline, proved to decrease both collagenase and gelatinase activity in cartilage from endstage hip osteoarthritis (97). These data suggest that an effective oral dose of doxycycline may be tolerated in a clinical trial to assess efficacious effects on cartilage degradation in osteoarthritic patients.

Other efforts to address the effects of enzymes such as collagenase and stromelysin on the extracellular matrix of cartilage have focused on synthetic compounds that can inhibit the enzymatic activity (98-100). This group of compounds includes chelating agents targeted to the metal dependency of the enzymes and molecules that are active site inhibitors and other agents that block enzyme synthesis. The success in the therapeutic arena has been complicated by the multifactorial nature of the disease process itself (101). A single effector molecule may only decrease one element in the cascade of degradative steps. If that step is early in the process of conversion of latent protein to active protein, the efficacy of the agent in question will be improved.

The recognition of the role of proinflammatory cytokines to the pattern of expression of cartilage degrading enzymes has resulted in a number of approaches to effectively counter their action. As a result, promising data are available that sequestration of proinflammatory agents by molecules such as interleukin-1 receptor antagonist (102,103,104) and antibody to tumor necrosis factor-alpha (105,106,107) can modulate progression of disease. Application of sets of anti-inflammatory cytokines could also intervene in the progression of osteoarthritis by countering the local synovitis associated with osteoarthritis (108,109).

Significant interest lies in the use of genetic methods to redirect tissue metabolism to offset the degradative cascade in joint (110,111). A number of efforts have already been directed to transfection of synovial cells as a means of regulating proinflammatory cytokine activity (112,113). These types of approaches will likely be extended to efforts to modulate degradative enzyme expression as well. Such a metabolic approach may permit a systematic block in the activation of cartilage degrading enzymes through the control to the intermediate steps in the processing of the latent to active enzyme.

10. CONCLUSIONS

The prevention of cartilage degradation in osteoarthritis remains a goal for clinician and scientists alike. The multitude of factors that initiate of the breakdown of the cartilage matrix will always remain a threat to normal joint function. Altering the character of the proteins composing the ECM will only be appropriate when the material properties of the ECM that permit functional load distribution can be preserved. In contrast, a fundamental understanding of the degradative enzymes that contribute to the ECM degradation and the mechanisms by which enzyme activation occurs will permit strategies for preserving joint function. The outcome of regulation of cartilage ECM degradation will be a significant reduction in patient morbidity and increased personal productivity. The degradative enzymes and tissues that may contribute the enzymes presented in this review provide guideposts for directing efforts to control cartilage degradation in osteoarthritis.

11. ACKNOWLEDGEMENTS

12. REFERENCES

1. D Heinegard & M Paulsson: Cartilage. In: Methods in enzymology, Academic Press, NY (1987)
2. JA Buckwalter, E Hunziker, LC Rosenberg, R Coutts, M Adams &.D Eyre: Articular cartilage: Composition and structure. In: Injury and repair of the musculoskeletal soft tissues. Eds: Woo SLY, Buckwalter JA: American Academy of Orthopaedic Surgeons, Rosemont, IL (1987)
3. D Heinegard & Y Sommarin: Proteoglycans: An overview. In: Methods in enzymology, Academinc Press, NY (1987)
4. GE Kempson: Mechanical properties of articular cartilage. In Adult articular cartilage. Ed: Freeman MAR: 2nd ed. Pitman Medical, Kent (1979)
5. R. A. Stockwell: The interrelationship of cell density and cartilage thickness in mammalian articular cartilage. *J Anat* 109, 411-21 (1971)
6. Aydelotte, M. B. & K.E. Kuettner: Differences between sub-populations of cultured bovine articular chondrocytes. I. Morphology and cartilage matrix production. *Connect Tissue Res* 18, 205-22 (1988)

7. M. B. Aydelotte, R. R. Greenhill & K. E. Kuettner: Differences between sub-populations of cultured bovine articular chondrocytes. II. Proteoglycan metabolism. *Connect Tissue Res* 18, 223-34 (1988)

8. P. D. Benya, P. D. Brown & S. R. Padilla: Microfilament modification by dihydrocytochalasin B causes retinoic acid-modulated chondrocytes to reexpress the differentiated collagen phenotype without a change in shape. *J Cell Biol* 106, 161-70 (1988)

9. E. N. Unemori & Z. Werb: Reorganization of polymerized actin: a possible trigger for induction of procollagenase in fibroblasts cultured in and on collagen gels. *J Cell Biol* 103, 1021-31 (1986)

10. E. J. Miller & V. J. Miller: Chick cartilage collagen: A new type of alpha 1 chain not present in bone or skin of the species. *Proc Natl Acad Sci USA* 64, 1264 (1969)

11. C. A Reese.& R. Mayne: Minor collagens of chick hyaline cartilage. *Biochemistry* 20, 5443-48 (1981)

12. H. J. Mankin, H. Dorfman, L. Lippiello & A. Zarins: Biochemical and metabolic abnormalities in articular cartilage form osteoarthritic hips. II. Correlation of morphology with biochemical and metabolic data. *J Bone Joint Surg (Am)* 53, 523-37 (1971)

13. R. Shuckett, R. & C, J. Malemud: Qualitative changes in human osteoarthritic hip cartilage proteoglycan synthesis during long-term explant culture. *Mech Ageing Dev* 46, 33-45 (1988)

14. Shuckett & C. J. Malemud: Proteoglycans synthesized by chondrocytes of human nonarthritic and osteoarthritic cartilage. *Proc Soc Exp Biol Med* 190, 275-81 (1989)

15. A. Maroudas: Balance between swelling pressure and collagen tension in normal and degenerate cartilage. *Nature* 260, 808-9 (1976)

16. M. B. Schmidt, V. C. Mow, L. E. Chun & D.R. Eyre: Effects of enzymatic extraction of proteoglycans on the tensile properties of articular cartilage. *J Orthop Res* 8, 353-63 (1990)

17. H. Muir, P. Bullough & A. Maroudas: The distribution of collagen in human articular cartilage with some of its physiological implications. *J Bone Joint Surg (Br)* 52, 554-63 (1970)

18. VC Hascall & D Heinegard: The structure of cartilage proteoglycans. In: Extracellular matrix influences on gene expression. Ed. by Slavkin, HC, Academic Press, NY (1975)

19. K. E.Kuettner & J. H. Kimura: Proteoglycans: an overview. *J. Cell Biochem* 27, 327-36 (1985)

20. D. Heinegard & V. C. Hascall: Aggregation of cartilage proteoglycans. III. Characteristics of the proteins isolated from trypsin digests of aggregates. *J Biol Chem* 249, 4250-60 (1974)

21. T. E. Hardingham & H. Muir: Hyaluronic acid in cartilage and proteoglycan aggregation. *Biochem* J 139, 565-81 (1974)

22. M. Morgelin, M. Paulsson, T. E. Hardinghan, D. Heinegard & J. L. Engel: Cartilage proteoglycans. Assembly with hyaluronate and link protein as studied by electron microscopy. *Biochem J* 253, 175-85 (1988)

23. T. E. Hardingham: Proteoglycans: Their structure, interactions and molecular organization in cartilage. Biochem Soc Trans 489-97 (1981)

24. S. Lohmander: Proteoglycans. *Bailliere's Clin. Rheumatol* 2, 37-62 (1988)

25. K. Doege, M. Sasaki, E. Horigan, J. R. Hassell & Y. Yamada: *J Biol Chem* 262, 17757-67 (1987)

26. M. G. Ehrlich, P. A. Houle, G. Vigliani & H. J. Mankin: Correlation between articular cartilage collagenase activity and osteoarthritis. *Arthritis Rheum* 21, 761-6 (1978)

27. A. Maroudas & M. Venn: Chemical composition and swelling of normal and osteoarthrotic femoral head cartilage. II. Swelling. *Ann Rheum Dis* 36, 399-406 (1977)

28. M. G. Ehrlich, A. L. Armstrong, B. V. Treadwell & H. J. Mankin: Degradative enzyme systems in cartilage. *Clin Orthop* 213, 62-8 (1986)

29. E. Vignon, O. Gateau, A. Martin, D. Hartmann, J. Bejui, M. C. Biol, M.T. Vanier, P. Louisot & M. Richard: Screening of degradative enzymes from articular cartilage in experimental osteoarthritis. *Clin Rheumatol* 6, 208-14 (1987)

30. J. P. Pelletier, J. Martel-Pelletier, D. S. Howell, L. Ghandur-Mnaymneh, J. E. Enis & J. F. Woessner Jr: Collagenase and collagenolytic activity in human osteoarthritic cartilage. *Arthritis Rheum* 26, 63-8 (1983)

31. M. G. Ehrlich, A. L. Armstrong, B.V. Treadwell, & H. J. Mankin: The role of proteases in the pathogenesis of osteoarthritis. *J Rheumatol* 14 Spec No:30-2 (1987)

32. J. Martel-Pelletier, J. P. Pelletier & C. J. Malemud: Activation of neutral metalloprotease in human osteoarthritic knee cartilage evidence for degradation in the core protein of sulphated proteoglycan. *Ann Rheum Dis* 47, 801-8 (1988)

33. M. J. Cox, C. A. McDevitt, S. P. Arnoczky & R. F. Warren: Changes in the chondroitin sulfate-rich region of articular cartilage proteoglycans in experimental osteoarthritis. *Biochim Biophys Acta* 840, 228-34 (1985)

34. G. Venn, J. J. Nietfeld, A. J. Duits, F. M. Brennan, E. Arner, M. Covington, M. E. Billingham & T. E. Hardingham: Elevated synovial fluid levels of interleukin-6 and tumor necrosis factor associated with early experimental canine osteoarthritis. *Arthritis Rheum* 36, 819-26 (1993)

35. H. E. Panula, L. S. Lohmander, S. Ronkko, U. Agren, H. J. Helminen & I. Kiviranta: Elevated levels of synovial fluid PLA2, stromelysin (MMP-3) and TIMP in early osteoarthrosis after tibial valgus osteotomy in young beagle dogs. *Acta Orthop Scand* 69, 152-8 (1998)

36. G. Keyszer, A. Redlich, T. Haupl, J. Zacher, M. Sparmann, U. Engethum, S. Gay & G. R. Burmester: Differential expression of cathepsins B and L compared with matrix metalloproteinases and their respective inhibitors in rheumatoid arthritis and osteoarthritis: a parallel investigation by semiquantitative reverse transcriptase-polymerase chain reaction and immunohistochemistry. *Arthritis Rheum* 41, 1378-87 (1998)

37. G. M. Keyszer, A. H. Heer, J. Kriegsmann, T. Geiler, A. Trabandt, M. Keysser, R. E. Gay & S. Gay: Comparative analysis of cathepsin L, cathepsin D, and collagenase messenger RNA expression in synovial tissues of patients with rheumatoid arthritis and osteoarthritis, by *in situ* hybridization. *Arthritis Rheum* 38, 976-84 (1995)

38. T. Iwase, Y. Hasegawa, N. Ishiguro, T. Ito, S. Iwasada, S. Kitamura & H. Iwata: Synovial fluid cartilage metabolism marker concentrations in osteonecrosis of the femoral head compared with osteoarthrosis of the hip. *J Rheumatol* 25, 527-31 (1998)

39. O. Lindy, Y. T. Konttinen, T. Sorsa, Y. Ding, S. Santavirta, A. Ceponis & C. Lopez-Otin: Matrix metalloproteinase 13 (collagenase 3) in human rheumatoid synovium. *Arthritis Rheum* 40, 1391-9 (1997)

40. K. Tsuchiya, W. J. Maloney, T. Vu, A. R. Hoffman, D. J. Schurman & R. L. Smith: RT-PCR analysis of MMP-9 expression in human articular cartilage chondrocytes and synovial fluid cells. *Biotech Histochem* 71, 208-13 (1996)

41. H.E. Jasin & J.T. Dingle: Human mononuclear cell factors mediate cartilage matrix degradation through chondrocyte activation. *J Clin Invest* 68, 571-81 (1981)

42. C.A. Towle, M.E. Trice, F. Ollivierra, B. J. Awbry & B. V. Treadwell: Regulation of cartilage remodeling by IL-1: evidence for autocrine synthesis of IL-1 by chondrocytes. *J Rheumatol* 14, (Spec No) 11-13 (1987)

43. G. W. Duff, F. di Govine & E. Dickens: Tumor necrosis factor and interleukin 1 in arthritis. *Immunobiology* 175, 10-11 (1987)

44. T. Krakauer, J. J. Oppenheim & H. E. Jasin: Human interleukin 1 mediates cartilage matrix degradation. Cell Immunol 91, 92-9 (1985)

45. J. R Hubbard, J. J. Steinberg, M.S. Bednar & C. B. Sledge: Effect of purified human interleukin-1 on cartilage degradation. *J Orthop Res* 6, 180-7 (1988)

46. R. L. Smith, A. C. Allison, & D. J. Schurman: Induction of articular cartilage degradation by recombinant interleukin 1alpha and 1beta. *Connect Tissue Res* 18, 307-16 (1989)

47. B. Henderson. & E. R. Pettipher: Arthritogenic actions of recombinant IL-1 and tumor necrosis factor alpha in the rabbit: evidence for synergistic interactions between cytokines *in vivo*. *Clin Exp Immunol* 75, 306-10 (1989)

48. R. A. Bunning & R. G. Russell: The effect of tumor necrosis factor alpha and gamma-interferon on the resorption of human articular cartilage and on the production of prostaglandin E and of caseinase activity by human articular chondrocytes. *Arthritis Rheum* 32, 780-4 (1989)

49. I. K. Campbell, P. J. Roughley & J. S. Mort: The action of human articular-cartilage metalloproteinase on proteoglycan and link protein. *Biochem J* 237, 117-122 (1986)

50. J. Schnyder, T. Payne & C. A. Dinarello: Human monocyte or recombinant interleukin 1's are specific for the secretion of a metalloproteinase from chondrocytes. *J Immunol* 138, 496-503 (1987)

51. M. Shinmei, T. Kikuchi, K. Masuda & Y. Shimomura: Effects of interleukin-1 and anti-inflammatory drugs on the degradation of human articular cartilage. *Drugs* 35(Suppl 1), 33-41 (1988)

52. F. Mehraban, S. Y. Kuo, H. Riera, C. Chang & R. W. Moskowitz: Prostromelysin and procollagenase genes are differentially up-regulated in chondrocytes from the knees of rabbits with experimental osteoarthritis. *Arthritis Rheum* 37, 1189-97 (1994)

53. M. T. Bayliss & Y. Ali: Studies on cathepsin B in human articular cartilage. *Biochem J* 171, 149-54 (1978)

54. A. I. Sapolsky, R. D. Altman, D. S. Howell & J. F. Woessner, Jr: Metalloproteases of human articular cartilage that digest cartilage proteoglycan at neural and acid pH. *J Clin Invest* 58, 1030-41 (1976)

55. J. F. Woessner Jr. & M. G. Selzer: Two latent metalloproteases of human articular cartilage that digest proteoglycan. *J Biol Chem* 259, 3633-38 (1984)

56. C. J. Malemud, D. P. Norby, A. I. Sapolsky, K. Matsuta, D. S. Howell & R. W. Moskowitz: Neutral proteinases from articular chondrocytes in culture. I. A latent collagenase that degrades human cartilage type II collagen. *Biochim Biophys Acta* 657, 517-29 (1981)

57. R. M. Hembry, G. Murphy, T. E. Cawston, J. T. Dingle & J. J. Reynolds: Characterization of specific antiserum for mammalian collagenase form several species: immunolocalization of collagenase in rabbit chondrocytes and uterus. *J Cell Sci* 81, 105-23 (1986)

58. G. Murphy, R. M. Hembry & J. J. Reynolds: Characterization of a specific antiserum to rabbit stromelysin and demonstration of the synthesis of collagenase and stromelysin by stimulated rabbit articular chondrocytes. *Coll Relat Res* 6, 351-63 (1986)

59. Q. Nguyen, J. S. Mort & P. J. Roughley: Preferential mRNA expression of prostromelysin relative to procollagenase and *in situ* localization in human articular cartilage. *J Clin Invest* 89, 1189-97 (1992)

60. J. F. Woessner Jr & Z. Gunja-Smith: Role of metalloproteinases in human osteoarthritis. *J Rheumatol Suppl* 27, 99-101 (1991)

61. A. J. Freemont, V. Hampson, R. Tilman, P. Goupille, Y. Taiwo & J. A. Hoyland: Gene expression of matrix metalloproteinases 1, 3, and 9 by chondrocytes in osteoarthritic human knee articular cartilage is zone and grade specific. *Ann Rheum Dis* 56, 542-9 (1997)

62. B. V. Shlopov, W. R. Lie, C. L. Mainardi, A. A. Cole, S. Chubinskaya & K. A. Hasty: Osteoarthritic lesions: involvement of three different collagenases. *Arthritis Rheum* 40, 2065-74 (1997)

63. F. Moldovan, J. P. Pelletier, J. Hambor, J. M. Cloutier & J. Martel-Pelletier: Collagenase-3 (matrix metalloprotease 13) is preferentially localized in the deep layer of human arthritic cartilage in situ: in vitro mimicking effect by transforming growth factor beta. *Arthritis Rheum* 40, 1653-61 (1997)

64. K. Imai, S. Ohta, T. Matsumoto, N. Fujimoto, H. Sato, M. Seiki & Y. Okada: Expression of membrane-type 1 matrix metalloproteinase and activation of progelatinase A in human osteoarthritic cartilage. *Am J Pathol* 151, 245-56 (1997)

65. M. Mohtai, R. L. Smith, D. J. Schurman, Y. Tsuji, F. M. Torti, N. I. Hutchinson, W. G. Stetler-Stevenson & G. I. Goldberg: Expression of a 92-kDa type IV collagenase/gelatinase by osteoarthritic cartilage and its induction in normal human articular cartilage by interleukin-1. *J Clinical Invest* 92, 179-85 (1993)

66. K. Tsuchiya, W. J. Maloney, T. Vu, A. R. Hoffman, P. Huie, R. Sibley, D. J. Schurman & R. L. Smith: Osteoarthritis: differential expression of matrix metalloproteinase-9 mRNA in nonfibrillated and fibrillated cartilage. *J Orthop Res* 15, 94-100 (1997)

67. A. Blanckaert, B. Mazieres, Y. Eeckhout & G. Vaes: Direct extraction and assay of collagenase from human

osteoarthritic articular cartilage. *Clin Chim Acta* 185, 73-9 (1989)

68. R. C. Billinghurst, L. Dahlberg, M. Ionescu, A. Reiner, R. Bourne, C. Rorabeck, P. Mitchell, J. Hambor, O. Diekmann, H. Tschesche, J. Chen, H. Van Wart & A. R. Poole: Enhanced cleavage of type II collagen by collagenases in osteoarthritic articular cartilage. *J Clin Invest* 99, 1534-45 (1997)

69. S. Ohta, K. Imai, K. Yamashita, T. Matsumoto, I. Azumano & Y. Okada: Expression of matrix metalloproteinase 7 (matrilysin) in human osteoarthritic cartilage. *Lab Invest* 78, 79-87 (1998)

70. S. Chubinskaya, G. Cs-Szabo & K. E. Kuettner: ADAM-10 message is expressed in human articular cartilage. *J Histochem Cytochem* 46, 723-9 (1998)

71. S. Chubinskaya, K. Huch, K. Mikecz, G. Cs-Szabo, K. A. Hasty, K. E. Kuettner & A. A. Cole: Chondrocyte matrix metalloproteinase-8: up-regulation of neutrophil collagenase by interleukin-1 beta in human cartilage from knee and ankle joints. *Lab Invest* 74, 232-40 (1996)

72. M. W. Lark, E. K. Bayne, J. Flanagan, C. F. Harper, L. A. Hoerrner, N. I. Hutchinson, I. I. Singer, S. A. Donatelli, J. R. Weidner, H. R. Williams, R. A. Mumford & L. S. Lohmander: Aggrecan degradation in human cartilage. Evidence for both matrix metalloproteinase and aggrecanase activity in normal, osteoarthritic, and rheumatoid joints. *J Clin Invest* 100, 93-106 (1997)

73. D. Ahrens, A. E. Koch, R. M. Pope, M. Stein-Picarella & M. J. Niedbala: Expression of matrix metalloproteinase 9 (96-kd gelatinase B) in human rheumatoid arthritis. *Arthritis Rheum* 39, 1576-87 (1996)

74. E. C. Arner & J. J. Kirkland: Effect of interleukin-1 on the size distribution of cartilage proteoglycans as determined by sedimentation field flow fractionation. *Biochim Biophys Acta* 993, 100-7 (1989)

75. J. A. Tyler: Articular cartilage cultured with catabolin (pig interleukin 1) synthesizes a decreased number of normal proteoglycan molecules. *Biochem J* 227, 869-78 (1985)

76. H. P. Benton & J. A. Tyler: Inhibition of cartilage proteoglycan synthesis by interleukin-1. *Biochem Biophys Res Commun* 154, 421-8 (1988)

77. J. J. Nietfeld, B. Wilbrink, W. den Otter & O. Huber Bruning: The effect of human interleukin-1 on proteoglycan metabolism in human and porcine cartilage explants. *J Rheumatol* 17, 818-26 (1990)

78. E. C. Arner: Effect of animal age and chronicity of interleukin-1 exposure on cartilage proteoglycan depletion in vivo. *J Orthop Res* 12, 321-30 (1994)

79. Y. Ogata, M. A. Pratta, H. Nagase & E. C. Arner: Matrix metalloproteinase 9 (92-kDa gelatinase/type IV collagenase) is induced in rabbit articular chondrocytes by cotreatment with interleukin 1 beta and a protein kinase C activator. *Exp Cell Res* 201, 245-9 (1992)

80. B. Lyons-Giordano, M. A. Pratta, W. Galbraith, G. L. Davis & E. C. Arner: Interleukin-1 differentially modulates chondrocyte expression of cyclooxygenase-2 and phospholipase A2. *Exp Cell Res* 206, 58-62 (1993)

81. D. D. Dean, J. Martel-Pelletier, J. P. Pelletier, D. S. Howell & J. F. Woessner Jr: Evidence for metalloproteinase and metalloproteinase inhibitor imbalance in human osteoarthritic cartilage. *J Clin Invest* 84, 678-85 (1989)

82. S. S. McCachren: Expression of metalloproteinases and metalloproteinase inhibitor in human arthritic synovium. *Arthritis Rheum* 34, 1085-93 (1991)

83. M. Zafarullah, S. Su, J. Martel-Pelletier, J. A. DiBattista, B. G. Costello, W. G. Stetler-Stevenson & J. P. Pelletier: Tissue inhibitor of metalloproteinase-2 (TIMP-2) mRNA is constitutively expressed in bovine, human normal, and osteoarthritic articular chondrocytes. *J Cell Biochem* 60, 211-7 (1996)

84. S. Su, F. Dehnade & M. Zafarullah: Regulation of tissue inhibitor of metalloproteinases-3 gene expression by transforming growth factor-beta and dexamethasone in bovine and human articular chondrocytes. *DNA Cell Biol* 15, 1039-48 (1996)

85. M. Zafarullah, J. P. Pelletier, J. M. Cloutier & J. Martel-Pelletier: Elevated metalloproteinase and tissue inhibitor of metalloproteinase mRNA in human osteoarthritic synovia. *J Rheumatol* 20, 693-7 (1993)

86. J. Martel-Pelletier, R. McCollum, N. Fujimoto, K. Obata, J. M. Cloutier & J. P. Pelletier: Excess of metalloproteases over tissue inhibitor of metalloprotease may contribute to cartilage degradation in osteoarthritis and rheumatoid arthritis. *Lab Invest* 70, 807-15 (1994)

87. R. M. Hembry, M. R. Bagga, J. J. Reynolds & D. L. Hamblen: Immunolocalisation studies on six matrix metalloproteinases and their inhibitors, TIMP-1 and TIMP-2, in synovia from patients with osteo- and rheumatoid arthritis. *Ann Rheum Dis* 54, 25-32 (1995)

88. C. A. Towle, M. Wright, A. C. Hecht, S. J. Kuong, L. E. Papanicolas, R. Totkovic, H. J. Mankin & B. V. Treadwell: A matrix metalloproteinase proenzyme activator produced by articular cartilage. *Biochem Biophys Res Commun* 247, 324-31 (1998)

89. F. H. Buttner, S. Chubinskaya, D. Margerie, K. Huch, J. Flechtenmacher, A. A. Cole, K. E. Kuettner & E. Bartnik: Expression of membrane type 1 matrix metalloproteinase in human articular cartilage. *Arthritis Rheum* 40, 704-9 (1997)

90. K. Imai, S. Ohta, T. Matsumoto, N. Fujimoto, H. Sato, M. Seiki & Y. Okada: Expression of membrane-type 1 matrix metalloproteinase and activation of progelatinase A in human osteoarthritic cartilage. *Am J Pathol* 151, 245-56 (1997)

91. A. Ratcliffe, M. P. Rosenwasser, F. Mahmud, P. A. Glazer, F. Saed-Nejad, N. Lane & V. C. Mow: The in vivo effects of naproxen on canine experimental osteoarthritic articular cartilage: composition, metalloproteinase activities and metabolism. *Agents Actions Suppl* 39, 207-11 (1993)

92. N. E. Lane, R. J. Williams III, D. J. Schurman, R. L. Smith: Inhibition of Interleukin-1 induced chondrocyte protease activity by a corticosteriod and a nonsteroidal anti-inflammatory drug. *J Rheumatol* 19, 135-9 (1992)

93. R. L. Smith, G. K. Kajiyama & N. E. Lane: Non-steroidal anti-inflammatory drugs: effects on normal human articular chondrocyte metabolism *in vitro*. *J Rheumatol* 22, 1130-37 (1995)

94. L. M. Golub, Ramamurthy & T. F. McNamara: Tetracyclines inhibit connective tissue breakdown: new therapeutic implications for an old family of drugs. *Crit Rev Oral Biol Med* 2, 297-322 (1991)

95. R. A. Greenwald, L. M. Golub, B. Lavietes, N. S. Ramamurthy, B Gruber, R. S. Laskin & T. F. McNamara: Tetracyclines inhibit human synovial collagenase *in vivo* and *in vitro*. *J Rheumatol* 14, 28-32 (1987)

96. L. P. Yu, G. N. Smith Jr, K. A. Hasty & K. D. Brandt: Doxycycline inhibits type XI collagenolytic activity of extracts from human osteoarthritic cartilage and of gelatinase. *J Rheumatol* 18, 1450-2 (1991)

97. G. N. Smith Jr, L. P. Yu, K. D. Brandt & W. N. Capello: Oral administration of doxycycline reduces collagenase and gelatinase activities in extracts of human osteoarthritic cartilage. *J Rheumatol* 25, 532-5 (1998)

98. M. A. Pratta: Biological evaluation of matrix metalloproteinase inhibitors. *Inflamm Res* 44:458-60 (1995)

99. M. Brewster, E. J. Lewis, K. L. Wilson, A. K. Greenham & K. M. Bottomley: Ro 32-3555, an orally active collagenase selective inhibitor, prevents structural damage in the STR/ORT mouse model of osteoarthritis. *Arthritis Rheum* 41, 1639-44 (1998)

100. K. M. Bottomley, W. H. Johnson & D. S. Walter: Matrix metalloproteinase inhibitors in arthritis. *J Enzyme Inhib* 13, 79-101 (1998)

101. S. Tanaka, C. Hamanishi, H. Kikuchi & K. Fukuda: Factors related to degradation of articular cartilage in osteoarthritis: a review. *Semin Arthritis Rheum* 27, 392-9 (1998)

102. J. Lewthwaite, S. Blake, R. C. Thompson, T. E. Hardingham & B. Henderson: Antifibrotic action of interleukin-1 receptor antagonist in lapine monoarticular arthritis. *Ann Rheum Dis* 54:591-6, (1995)

103. J.P. Caron, J. C. Fernandes, J. Martel-Pelletier, G. Tardif, F. Mineau, C. Geng & J. P. Pelletier: Chondroprotective effect of intraarticular injections of interleukin-1 receptor antagonist in experimental osteoarthritis. Suppression of collagenase-1 expression. *Arthritis Rheum* 39:1535-44 (1996)

104. A. Bendele, T. McAbee, G. Sennello, J. Frazier, E. Chlipala & D. McCabe: Efficacy of sustained blood levels of interleukin-1 receptor antagonist in animal models of arthritis: comparison of efficacy in animal models with human clinical data. *Arthritis Rheum* 42:498-506 (1999)

105. E. Paleolog: Target effector role of vascular endothelium in the inflammatory response: insights from the clinical trial of anti-TNF alpha antibody in rheumatoid arthritis. *Mol Pathol* 50:225-33 (1997)

106. F. M. Brennan, K. A. Browne, P. A. Green, J. M. Jaspar, R. N. Maini & M. Feldmann: Reduction of serum matrix metalloproteinase 1 and matrix metalloproteinase 3 in rheumatoid arthritis patients following anti-tumour necrosis factor-alpha (cA2) therapy. *Br J Rheumatol* 36:643-50 (1997)

107. R. N. Maini, M. J. Elliott, F. M. Brennan, R. O. Williams, C. Q. Chu, E. Paleolog, P. J. Charles, P. C. Taylor & M. Feldmann: Monoclonal anti-TNF alpha antibody as a probe of pathogenesis and therapy of rheumatoid disease. *Immunol Rev* 144:195-223 (1995)

108. P. Isomaki & J. Punnonen: Pro- and anti-inflammatory cytokines in rheumatoid arthritis. *Ann Med* 29:499-507 (1997)

109. M.D. Smith, S. Triantafillou, A. Parker, P. P. Youssef & M. J. Coleman: Synovial membrane inflammation and cytokine production in patients with early osteoarthritis. *J Rheumatol* 24:365-71 (1997)

110. J. J. Nietfeld, A. J. Duits, M. G. J. Tilanus, M. E. Van Den Bosch, W. Den Otter, P. J. A. Capel & W. J. Bijlsma: Antisense oligonucleotides, a novel tool for the control of cytokine effects on human cartilage. *Arthritis Rheum* 37, 1357-62 (1994)

111. C. E. Brinckerhoff: Regulation of metalloproteinase gene expression: implications for osteoarthritis. *Crit Rev Eukaryot Gene Expr* 2, 145-164 (1992)

112. S. C. Ghivizzani, E. R. Lechman, R. Kang, C. Tio, J. Kolls, C. H. Evans & P. D. Robbins: Direct adenovirus-mediated gene transfer of interleukin 1 and tumor necrosis factor alpha soluble receptors to rabbit knees with experimental arthritis has local and distal anti-arthritic effects. *Proc Natl Acad Sci U S A* 95, 4613-8 (1998)

113. D. Jaffurs & C. H. Evans: The human genome project: implications for the treatment of musculoskeletal disease. *J American Academy Orthopaedic Surgeons* 6, 1-14 (1998)